Matching articles for "Evrysdi"

In Brief: Risdiplam (Evrysdi) for Spinal Muscular Atrophy (online only)

   
The Medical Letter on Drugs and Therapeutics • July 26, 2021;  (Issue 1629)
Risdiplam (Evrysdi – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients ≥2 months old. It is...
Risdiplam (Evrysdi – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients ≥2 months old. It is the first oral drug to be approved in the US for treatment of SMA; nusinersen (Spinraza), an intrathecally administered SMN2-directed antisense oligonucleotide, and onasemnogene abeparvovec (Zolgensma), an IV adeno-associated virus vector-based gene therapy, were approved earlier.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):e1-2 | Show Full IntroductionHide Full Introduction